PALISADE BIO INC

For the period ended Sep 30, 2024. Filed Nov 12, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 12, 2024

PALI$1.13-5.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

Preferred Stock · Common Stock · AdditionalPaid-inCapital* · AccumulatedDeficit · TotalStockholders'Equity
Shares · Amount · Shares* · Amount*
Balance, June 30, 2024	200,000	$2	966,345	$9	$139,051	$(129,113)	$9,949
Net loss	—	—	—	—	—	(3,487)	(3,487)
Stock-based compensation expense and related charges	—	—	—	—	95	—	95
Issuance of common stock to vendors	—	—	14,029	—	51	—	51
Issuance of common stock in connection with exercise of warrants	—	—	218,142	2	(2)	—	—
Balance, September 30, 2024	200,000	$2	1,198,516	$11	$139,195	$(132,600)	$6,608

Preferred Stock · Common Stock · AdditionalPaid-inCapital* · AccumulatedDeficit · TotalStockholders'Equity
Shares · Amount · Shares* · Amount*
Balance, June 30, 2023	200,000	$2	456,622	$4	$130,717	$(114,923)	$15,800
Net loss	—	—	—	—	—	(3,596)	(3,596)
Stock-based compensation expense and related charges	—	—	—	—	202	—	202
Issuance of common stock for vesting of restricted stock units, net of employee withholding tax liability	—	—	1,466	—	—	—	—
Issuance of common stock and warrants in September 2023 Offering, net of issuance costs of $345	—	—	155,959	2	1,674	—	1,676
Adjustment to record the impact of exercise price reset on outstanding warrants related to down round provisions	—	—	—	—	16	(16)	—
Balance, September 30, 2023	200,000	$2	614,047	$6	$132,609	$(118,535)	$14,082

(*) Adjusted to reflect the 1-for-15 reverse stock split effected on April 5, 2024.

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

Preferred Stock · Common Stock · AdditionalPaid-inCapital* · AccumulatedDeficit · TotalStockholders'Equity
Shares · Amount · Shares* · Amount*
Balance, December 31, 2023	200,000	$2	618,056	$6	$132,811	$(121,506)	$11,313
Net loss	—	—	—	—	—	(11,094)	(11,094)
Stock-based compensation expense and related charges	—	—	—	—	575	—	575
Issuance of common stock to vendors	—	—	29,632	—	124	—	124
Issuance of common stock for vesting of restricted stock units, net of employee withholding tax liability	—	—	17,270	—	(25)	—	(25)
Issuance of common stock in connection with exercise of warrants	—	—	218,142	2	(2)	—	—
Issuance of common stock under Employee Stock Purchase Plan	—	—	2,256	—	11	—	11
Issuance of common stock in connection with warrant inducement, net of issuance costs of $2,412 (Note 5)	—	—	228,162	2	2,158	—	2,160
Issuance of common stock and warrants in May 2024 Offering, net of issuance costs of $705	—	—	85,100	1	3,543	—	3,544
Reverse stock split fractional share settlement	—	—	(102)	—	—	—	—
Balance, September 30, 2024	200,000	$2	1,198,516	$11	$139,195	$(132,600)	$6,608

Preferred Stock · Common Stock · AdditionalPaid-inCapital* · AccumulatedDeficit · TotalStockholders'Equity
Shares · Amount · Shares* · Amount*
Balance, December 31, 2022	200,000	$2	196,287	$2	$121,665	$(109,190)	$12,479
Net loss	—	—	—	—	—	(9,329)	(9,329)
Stock-based compensation expense and related charges	—	—	—	—	439	—	439
Issuance of common stock for vesting of restricted stock units, net of employee withholding tax liability	—	—	2,310	—	—	—	—
Issuance of common stock in connection with exercise of warrants	—	—	146,932	1	1,349	—	1,350
Issuance of common stock and warrants in January 2023 Offering, net of issuance costs of $507	—	—	31,789	—	2,166	—	2,166
Issuance of common stock and warrants in April 2023 Offering, net of issuance costs of $854	—	—	80,770	1	5,300	—	5,301
Issuance of common stock and warrants in September 2023 Offering, net of issuance costs of $345	—	—	155,959	2	1,674	—	1,676
Adjustment to record the impact of exercise price reset on outstanding warrants related to down round provisions	—	—	—	—	16	(16)	—
Balance, September 30, 2023	200,000	$2	614,047	$6	$132,609	$(118,535)	$14,082

(*) Adjusted to reflect the 1-for-15 reverse stock split effected on April 5, 2024.

Condensed Consolidated Stateme

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.